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821-3 Amlodlplne Decreases Myocardial Oxygen 
Consumption via Angiotenain 4 Receptor: A Unique 
Effect of the R+ Enantiomer 
Seema Mital, Edward Shesely, Thomas H, Hintze, Columbia University, New York, New 
York, New York Medical College, Valhalla, New York. 
Background: Amlodipine decreases myocardial oxygen consumption (MVO2) via R+ 
enantiomer mediated endothelial nitric oxide (NO) release. We investigated the role of 
angiotensin (AT) 2 and 4 receptors in mediating this effect. 
Methods: We measured MVO2 in vitro using the Clark type oxygen electrode in isolated 
LV myocardial segments obtained from (i) wild-type and AT2 receptor knock-out (KD) 
mice (n=5), and (ii) explanted failing human hearts obtained at the time of heart trans- 
plantation (n=2). We studied the effect of increasing doses of R+ enantiomer (10-7M -10- 
5 M) on MVO2 with and without (i) NO synthase inhibitor, nitro-L-arginine methyl ester (L- 
NAME, 10-3 M), (ii) AT2 receptor blocker, PD 123319, 10-6-10-5M, and (iii) specific AT4 
receptor blocker, divalyl angiotensin 4,10-5M. 
Results: Wild-type mice: R+ caused a dose-dependent decrease in MVO2 (-24±8% at 
highest dose, p<O,05). This effect was inhibited by L-NAME (-17±7%) and 10-5M PD 
123319 (2±7%). AT2 KO mice: R+ caused a dose-dependent decrease in MVO2 (- 
25±3% at highest dose, p<0.05) and this was not blocked by 10-6M PD123319, selective 
AT2 receptor antagonist suggesting an alternate receptor/pathway. At higher concentra- 
tion of 10-5M, PD123319 blocked the effect of R+ (-5±2%, p<0.01). At this dose, PD 
compound appears to be a nonselective AT receptor antagonist possibly acting on AT4 
receptor, L-NAME caused a 33% reduction in the effect of R+. Human myocardium: R+ 
decreased MVO2 with a -20±1% decrease at highest dose. This effect was attenuated by 
both L-NAME and 10-5M PD123319. Also, specific AT4 receptor blocker caused a 50% 
attenuation of R+ effect. Conclusion: The R+ enantiomer of amlodipine decreases MVO2 
by AT4 receptor mediated NO release in AT2 receptor knock-out mice. In failing human 
myocardium, this effect also appears to be mediated by AT4 receptors. 
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821-4 Angiotensin II Receptor Antagonism and ACE Inhibition 
Ameliorate Hyperinsulinemia and Obesity in a Murine 
Model of Polygenic Obesity 
Jan R. Ortleoc. Jutta Breuer, Karin Kluge, Reinhard Kluge, Hans-Georg Joost, Medical 
Clinic I RWTH University Hospital, Aachen, Germany, Institute for Pharmacology and 
Toxicology, Aachen, Germany 
Background: ACE inhibitors are well established in the prevention of hypertension- 
associated complications of the metabolic syndrome. This study was performed in order 
to assess the effects of the ACE inhibitor captopril and of the angiotensin II receptor 
antagonist irbesartan on other conditions of the metabolic syndrome in an animal model. 
Methods: Male NZO/BL6 F1 mice were treated with captopril, irbesartan, or placebo for 
ten months. Treatment with captopril and irbesartan in equivalent dosage was controlled 
by monitoring the blood pressure (BP). At the end of the study, gain of body weight (BW), 
serum levels of insulin, cholesterol, triglycerides and creatinine, cardiac weight and 
degree of atherosclerosis were determined. 
Results: Control animals treated with placebo developed a metabolic syndrome with 
obesity (55.5 + 6.3 g), hypertension (t46 + 10 mmHg), hyperinsulinemia (7.2 + 5.7 ng/ 
ml), hypercholesterolemia (5.1 + 0.7 mmoVI), cardiac hypertrophy (269 + 44 mg) and ath- 
erosclerotic plaques in the ascending aorta (3.6 + 1.5 p.rr~). Treatment with ACE inhibitor 
or angiotensin II receptor antagonist significantly (p<0.001) reduces hypertension (73 + 5 
and 78 + 11 mmHg), cardiac hypertrophy (203 + 26 and 202 + 18 mg) and atherosclero- 
sis (2.2 _+ 0.9 and 1.8 _+ 0.8 Hm2). In addition captopril and irbesartan prevented the devel- 
opment of obesity (42.2 + 3.5 and 38.3 ± 2.8 g) and hyperinsulinemia (3.6 ± 1.5 and 1.8 
± 0.4 ng/ml), Irbesartan being somewhat more effective than captopril in the prevention 
of hyperinsulinemia (p<0.01). 
Conclualon: In a mouse model of the obesity associated metabolic syndrome, long term 
treatment with an ACE inhibitor or an angiotensin II receptor antagonist, can ameliorate 
obesity and hypednsufinemia. 
Noon 
821-5 Chronic Angiotensin II (AT1) Receptor Antagonism 
Selectively Enhances Renal cGMP Production With 
Improved Renal Function in Experimental Overt 
Congestive Heart Failure 
Homo H. Chert, John B. Osborn, Gall J. Harry, John C. Burnett, Jr., Mayo Clinicand 
Foundation, Rochester, Minnesota. 
BACKGROUND: Recent studies have reported that preservation of renal function is an 
important predictor of survival in congestive heart failure (CHF). A hallmark of overt CHF 
is an attenuated renal cGMP production to endogenous natriuretic peptides (NPs) and 
nitdc oxide (NO), which may lead to decline in renal function. Studies have also shown 
that Angiotensin II (ANG II) activates cGMP phosphodiesterase resulting in increased 
cGMP degradation. We therefore hypothesized that chronic AT1 receptor antagonism 
would restore the renal cGMP production in response to endogenous NPs and NO as 
assessed by urinary cGMP with improved sodium excretion. 
METHODS: We determined the cardiorenal actions of chronic AT1 blockade (Valsartan, 
Novartis, 320 mg daily for 10 days, n=5) in a canine model rapid ventricular pacing 
induced overt CHF (245 bpm for 10 days) as compared to a non-treated group (n=5). 
RESULTS: After 10 days of chronic AT1 receptor antagonism, urinary sodium excretion 
increased (12.4 ± 3.3 vs 2.7 ± 1.3 uEq/min,p<0.05) in association with a marked increase 
in urinary cGMP excretion (1558 ± 200 vs 139 ±65 pmol/min, p<0.05) as compared to the 
non-treated group. The natriuretic response to chronic AT1 receptor antagonism was 
localized to the inner medullary collecting duct by the lithium clearance technique, a 
nephron site rich in NPs receptors and sensitive to NO, as distal tubular fractional sodium 
reabsorption decreased in the AT1 blocker group vs non-treated group (97.6 ± 0.3 vs 
98.9 ± 0.5 %, p<O.05). These renal responses where selective as they occurred in the 
absence of any changes in plasma NPs or cGMP. Chronic AT1 receptor antagonism also 
reduced cardiac filling pressures consistent with cardiac unloading. 
CONCLUSION: We conclude that chronic AT1 receptor antagonism in experimental 
overt CHF enhances renal cGMP production, the common secondary messenger for the 
NPs and NO system resulting in improved renal tubular function and sodium excretion. 
This study provides insight into renal and humoral pathophysiological actions of ANG II 
and the AT1 receptor in CHF and mechanisms by which AT1 receptor antagonism may 
mediate beneficial therapeutic properties by targeting the kidney in this disease state. 
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1108-71 Optical Imaging of Adenoviral Mediated Cardiac Gene 
Expression in Living Rats 
Joseoh C. Wu, Masa Inubushi, Heinrich Schelbert, Sanjiv S. Gambhir, UCLA Schoolof 
Medicine, Los Angeles, California, 
Background: Direct injection of edenovirus into the heart is useful for studying reporter 
gene constructs. However, most studies rely on postmortem analysis. We have validated 
a novel method of studying rat cardiac gene expression of CMV driven firefly luciferase 
(Ad-CMV-FL) utilizing a cooled Charged Couple Detector (CCD) camera. 
Methods: Rats underwent a standard thoracotomy. In one group, lx10 s pfu was injected 
into left ventdcular wall (n=3). Another group received serially diluted titers (lx109 to 
lx l  06 pfu). Control rats were injected with 1 x109 pfu of Ad-CMV-HSV1-sr39tk expressing 
mutant hymidine kinase (n=3). Images were acquired on days 2 and 5 after i.p. injection 
of luciferin (125 mg/kg) and data expressed as relative light unit per minute (RLU/min). 
Results: Rats imaged serially show cardiac FL activity of 172,423 ± 8,066 (clay 2) and 
252,755 ± 83,739 RLU/min (day 5). Rats injected with diluted titers show considerable FL 
activity at day 5:1,452 RLU/min (Ix107 pfu) and 248 RLU/min (lx10 s pfu). All values are 
statistically significant (p<0.05) compared to control rats showing background signals 
(10±5 RLU/min). 
Conclusion: In summary, this study demonstrates the feasibility of imaging the location, 
magnitude, and persistence of cardiac reporter gene expression in rats over time. The 
cooled CCD camera produces consistent results and the detection sensitivity is very 
high, down to lx10 s pfu. This is the first demonstration of imaging cardiac gene expres- 
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1105-72 DNA Chip Analysis of Akt-Regulated Genes in 
Endothelial Cells Reveals Activation of Many 
Proangiogenic Pathways 
Hvo-Soo Kim. Yuri Ivashchenko, Kenneth Walsh, Boston University Medical Center, 
Boston, Massachusetts, Seoul National University Hospital, Seoul, South Korea. 
Background: The serine-threonine protein kinase Aktl is activated downstream of 
numerous angiogenic factors in endothelial cells. To understand the role of this signaling 
pathway in the angiogenic response, we used adenovirus-mediated Aktl gene transfer 
and high-throughput affymatrix oligonucleotide microarrays to examine the Akt-regulated 
genes in human umbilical vein endothelial cells (HUVEC). 
Methods: HUVEC were either mock-infected or infected with adenoviral vectors 
expressing constitutively-active Aktl or ~-galactosidase (moi=100). Under these condi- 
tions, transfection efficiency was 95% or greater. At 24 hours post-treatment, RNAs were 
isolated, labelled during reverse-transcription, and hybridized to oligonucleotide microar- 
rays, the Human Genome U95A array. The genes that showed a significant change of 
expression (>2-fold increase or decrease) in both replicate and duplicate assays were 
selected and confirmed by quantitative PCR. 
Results: Constitutive activation of Akt signaling altered the expression of 130 genes of a 
total of 12,000 genes analyzed. Consistent with the pro-angiogenic role attributed to Akt, 
there were many angiogenesis-related growth factors and cytokines that were induced 
by an increase in Akt signaling. These include VEGF-A, VEGF-C, IL-8, GRO(Growth 
Regulated Oncogene)-c~, GRO-13, GRO-y, Cox2, HOX, and heme oxygenase-1. Akt sig- 
naling also induced the expression of adhesion molecules (VCAM-1, ICAM-1, ELAM-1) 
associated with endothelial cell activation. As expected from the documented pro-sur- 
vival action of Akt, several anti-apoptotic genes (HSP70) were increased. Akt also 
increased a series of genes involved in the cholesterol synthesis. Finally, Akt exagger- 
